Developer docs
API playgroundTry for free, no card

Search company profiles

Hemoclear

Full company profile

uuid002cry5

Namestring
Hemoclear
Legal namestring
HemoClear B.V.
Websiteurl
hemoclear.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

HemoClear B.V. is a Dutch medical device company headquartered in Zwolle, Netherlands, that develops and commercializes an autologous blood transfusion system for surgical, trauma, obstetric, and global health applications. The company serves hospital surgical departments (cardiac, vascular, orthopedic, spine, neurosurgery, transplantation, obstetrics), military and emergency medical services, and healthcare programs in low-resource settings where donor blood is scarce or unavailable. The company's stated mission is to address complications, high costs, and supply shortages associated with allogeneic donor blood transfusion by enabling use of a patient's own shed blood.

The company's core product is a first-in-class, gravity-driven micro-filtration blood filter that uses medical-grade polyurethane film — bombarded with argon ions in a vacuum — to capture red blood cells and platelets from patient shed blood while filtering out plasma toxins, harmful agents, and activated factors. Unlike centrifugal cell savers, the device requires no electricity, centrifuge, or specialized equipment, can be operated by any healthcare professional, and produces up to 8 units of platelet-rich autologous transfusion blood in 4 hours (procedure time ~30 minutes, set-up 3–5 minutes). The filter received CE Mark approval in March 2021 and is manufactured under ISO 13485:2016; production has been centralized in the Netherlands and scaled through a partnership with VDL: Dutch PPE Solutions in Heerlen.

HemoClear generates revenue primarily through B2B hardware sales of single-use filter kits (HC01K), blood collection reservoirs, and accessories, sold to hospitals via direct enterprise field sales and exclusive territory distributors. Go-to-market combines direct hospital engagement, channel partners (Pennine Healthcare for UK/Ireland, Medista for Czech Republic), conference-driven outreach to anesthesiologists and surgeons, and grant-funded global health partnerships (e.g., Nigeria NBSA, South Africa rural programs). Pricing is quote-based and not publicly disclosed; published evidence cites up to $422 per-case cost savings, 18–33% reductions in allogeneic transfusion rates in spine surgery, and 40%/37% reductions in cardiac and open aortic surgery.

Short descriptiontext

HemoClear B.V. is a Dutch medical device company that develops a gravity-driven micro-filtration blood filter enabling autologous blood transfusion for hospital surgical, trauma, obstetric, and low-resource healthcare settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersZwolle, Netherlands
HQ citystring
Zwolle
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous blood transfusion, cell salvage devices, medical device manufacturing, patient blood management, micro-filtration blood filters
Industry2 codes
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Autologous Blood Transfusion Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1HemoClear Filter Kits
TypeHardware Sales
Description

Sale of medical device filter kits comprising all necessary components for cell salvage procedures. Product catalog includes HC01K – 10 Filter kits and blood collection reservoirs. Single-use device sold to hospitals and healthcare facilities.

hemoclear.com
2Accessories and Consumables
TypeHardware Sales
Description

Related accessories and consumables for the HemoClear blood system including blood collection reservoirs with connection tubes, thorax drainage sets, and post-op collection drains.

hemoclear.com
3Manufacturing Partnership with VDL
TypeHardware Sales
Description

Partnership with VDL: Dutch PPE Solutions for manufacturing the HemoClear autologous blood filter, adding to their healthcare portfolio while HemoClear focuses on innovation and commercialization.

hemoclear.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1HemoClear filter kit products (HC01K - 10 Filter kits, C0000002 - Blood Collection Reservoir)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Product catalog visible on website but no prices listed publicly. Order form available for hospitals to request quotes.

hemoclear.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HemoClear develops and manufactures a gravity-driven micro-filtration autologous blood transfusion system. Its core product, the HemoClear Autologous Blood Filter, captures red blood cells and platelets from patient shed blood while filtering out plasma, toxins, and harmful agents, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The company sells filter kits, blood collection reservoirs, and accessories to hospitals, surgical departments, and global health programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 78% reduction in ICU mortality for COVID-19 patients treated with HemoClear-obtained convalescent plasma
+7 more records
Product overview1 text field

HemoClear offers a micro-filtration based autologous blood transfusion system centered around the HemoClear Autologous Blood Filter. The core product is a gravity-driven bedside filtration device that washes and filters patient shed blood to capture red blood cells and platelets, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The product portfolio includes the main HemoClear filter, HC01K Filter Kits (packages of 10 filters), Blood Collection Reservoirs with connection tubes, and an Accessories Kit developed with Pennine Healthcare. The system enables any healthcare professional to perform cell salvage without electricity, centrifuges, or expensive equipment, generating up to 8 units of autologous transfusion blood in 4 hours.

Product and service4 records
1HemoClear Autologous Blood Filter
CategoryAutologous blood transfusion core device
Description

A gravity-driven micro-filtration blood filter that captures red blood cells and platelets from patient shed blood, separating them from plasma, toxins, and pathological elements for autologous transfusion. Device set-up takes 3-5 minutes, with the complete procedure taking approximately 30 minutes and generating up to 8 units of high-quality autologous transfusion blood in 4 hours. Designed for hospital surgical departments, obstetric care, and military/emergency settings.

2HC01K Filter Kit
3Blood Collection Reservoir with Connection Tube
CategoryBlood collection accessory
Description

Blood collection reservoir with connection tube (product code C0000002) for collecting patient shed blood during or after surgery, designed as a compatible accessory to the HemoClear filter system, including thorax drainage sets and post-op collection drains.

4HemoClear Accessories Kit
CategoryAccessories kit
Description

Complete ready-to-use accessories kit developed with Pennine Healthcare, containing all material needed to recuperate red blood cells from patient shed blood for autologous transfusion, manufactured by Pennine Healthcare as exclusive UK and Ireland distributor.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

LivaNova's Sorin Group legacy includes the XTRA and Electa autologous cell-salvage consoles, which compete directly with HemoClear in cardiac and major surgery settings.

TypeEmerging player
Description

CytoSorbents' CytoSorb blood-purification technology operates in adjacent intraoperative and ICU blood-filtration applications, partially overlapping with HemoClear's positioning in surgical and critical-care blood management.

TypeEmerging player
Description

Velico Medical focuses on front-line blood product processing and storage technologies for transfusion medicine, addressing a similar end-customer (blood banks and surgical teams) as HemoClear.

TypeBroad incumbent
Description

Fresenius Kabi offers a broad portfolio of blood collection, processing, and transfusion devices (including CompoFlow and related consumables), positioning it as a broad incumbent across the transfusion-medicine supply chain that overlaps with HemoClear.

TypeBroad incumbent
Description

Medtronic's historical perfusion and cell-saver franchises (e.g., the autolog system) compete in the same surgical cell-salvage category as HemoClear, although Medtronic has a much broader device portfolio.

TypeDirect peer
Description

Brightwake produces autologous blood filtration devices (e.g., Hemafuse) for surgical cell salvage in low-resource settings, making it one of the closest direct peers to HemoClear's gravity-driven filter concept.

7Haemonetics
TypeDirect peer
Description

Haemonetics' Cell Saver system is the dominant centrifugal autologous blood cell-salvage device used in operating rooms globally, competing head-to-head with HemoClear's micro-filtration filter in surgical departments.

TypeBroad incumbent
Description

Terumo BCT provides Spectra Optia and other apheresis/cell-processing systems used in operating rooms and blood banks, serving as a broad incumbent in cell salvage and blood component processing.

TypeOthers
Description

Pennine Healthcare is HemoClear's exclusive UK/Ireland distributor and co-developer of the HemoClear Accessories Kit, making it a partner rather than competitor but highly relevant as a channel comparison for autologous blood device go-to-market.

TypeEmerging player
Description

i-SEP is a French medtech developing an innovative autologous whole-blood filtration system for surgical and trauma settings, overlapping directly with HemoClear's filtration approach and target use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemoclear

Autologous Blood Transfusion Deviceshemoclear.com

HemoClear B.V. is a Dutch medical device company that develops a gravity-driven micro-filtration blood filter enabling autologous blood transfusion for hospital surgical, trauma, obstetric, and low-resource healthcare settings.

What Hemoclear does

HemoClear B.V. is a Dutch medical device company headquartered in Zwolle, Netherlands, that develops and commercializes an autologous blood transfusion system for surgical, trauma, obstetric, and global health applications. The company serves hospital surgical departments (cardiac, vascular, orthopedic, spine, neurosurgery, transplantation, obstetrics), military and emergency medical services, and healthcare programs in low-resource settings where donor blood is scarce or unavailable. The company's stated mission is to address complications, high costs, and supply shortages associated with allogeneic donor blood transfusion by enabling use of a patient's own shed blood.

The company's core product is a first-in-class, gravity-driven micro-filtration blood filter that uses medical-grade polyurethane film — bombarded with argon ions in a vacuum — to capture red blood cells and platelets from patient shed blood while filtering out plasma toxins, harmful agents, and activated factors. Unlike centrifugal cell savers, the device requires no electricity, centrifuge, or specialized equipment, can be operated by any healthcare professional, and produces up to 8 units of platelet-rich autologous transfusion blood in 4 hours (procedure time ~30 minutes, set-up 3–5 minutes). The filter received CE Mark approval in March 2021 and is manufactured under ISO 13485:2016; production has been centralized in the Netherlands and scaled through a partnership with VDL: Dutch PPE Solutions in Heerlen.

HemoClear generates revenue primarily through B2B hardware sales of single-use filter kits (HC01K), blood collection reservoirs, and accessories, sold to hospitals via direct enterprise field sales and exclusive territory distributors. Go-to-market combines direct hospital engagement, channel partners (Pennine Healthcare for UK/Ireland, Medista for Czech Republic), conference-driven outreach to anesthesiologists and surgeons, and grant-funded global health partnerships (e.g., Nigeria NBSA, South Africa rural programs). Pricing is quote-based and not publicly disclosed; published evidence cites up to $422 per-case cost savings, 18–33% reductions in allogeneic transfusion rates in spine surgery, and 40%/37% reductions in cardiac and open aortic surgery.

Hemoclear firmographics

Firmographics
Name
Hemoclear
Legal name
HemoClear B.V.
Website
https://hemoclear.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
HemoClear B.V. is a Dutch medical device company that develops a gravity-driven micro-filtration blood filter enabling autologous blood transfusion for hospital surgical, trauma, obstetric, and low-resource healthcare settings.
Ownership category
akta.pro rank

Hemoclear industry classification

Industry
Product category
Autologous Blood Transfusion Devices
NAICS
Blood and Organ Banks (621991)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Autologous blood transfusion
  • Cell salvage devices
  • Medical device manufacturing
  • Patient blood management
  • Micro-filtration blood filters

Where Hemoclear is headquartered

Location

Headquarters

HQ city
Zwolle
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Hemoclear business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. HemoClear Filter Kits: Sale of medical device filter kits comprising all necessary components for cell salvage procedures. Product catalog includes HC01K – 10 Filter kits and blood collection reservoirs. Single-use device sold to hospitals and healthcare facilities.
  2. Accessories and Consumables: Related accessories and consumables for the HemoClear blood system including blood collection reservoirs with connection tubes, thorax drainage sets, and post-op collection drains.
  3. Manufacturing Partnership with VDL: Partnership with VDL: Dutch PPE Solutions for manufacturing the HemoClear autologous blood filter, adding to their healthcare portfolio while HemoClear focuses on innovation and commercialization.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHemoClear filter kit products (HC01K - 10 Filter kits, C0000002 - Blood Collection Reservoir)

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Hemoclear product offering

Product offering

Core offering

HemoClear develops and manufactures a gravity-driven micro-filtration autologous blood transfusion system. Its core product, the HemoClear Autologous Blood Filter, captures red blood cells and platelets from patient shed blood while filtering out plasma, toxins, and harmful agents, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The company sells filter kits, blood collection reservoirs, and accessories to hospitals, surgical departments, and global health programs.

Product overview

HemoClear offers a micro-filtration based autologous blood transfusion system centered around the HemoClear Autologous Blood Filter. The core product is a gravity-driven bedside filtration device that washes and filters patient shed blood to capture red blood cells and platelets, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The product portfolio includes the main HemoClear filter, HC01K Filter Kits (packages of 10 filters), Blood Collection Reservoirs with connection tubes, and an Accessories Kit developed with Pennine Healthcare. The system enables any healthcare professional to perform cell salvage without electricity, centrifuges, or expensive equipment, generating up to 8 units of autologous transfusion blood in 4 hours.

Differentiator

Problem solved

Functional benefit

Products and services

  • HemoClear Autologous Blood Filter A gravity-driven micro-filtration blood filter that captures red blood cells and platelets from patient shed blood, separating them from plasma, toxins, and pathological elements for autologous transfusion. Device set-up takes 3-5 minutes, with the complete procedure taking approximately 30 minutes and generating up to 8 units of high-quality autologous transfusion blood in 4 hours. Designed for hospital surgical departments, obstetric care, and military/emergency settings.
  • HC01K Filter Kit
  • Blood Collection Reservoir with Connection Tube Blood collection reservoir with connection tube (product code C0000002) for collecting patient shed blood during or after surgery, designed as a compatible accessory to the HemoClear filter system, including thorax drainage sets and post-op collection drains.
  • HemoClear Accessories Kit Complete ready-to-use accessories kit developed with Pennine Healthcare, containing all material needed to recuperate red blood cells from patient shed blood for autologous transfusion, manufactured by Pennine Healthcare as exclusive UK and Ireland distributor.

Quantifiable outcome

  • 78% reduction in ICU mortality for COVID-19 patients treated with HemoClear-obtained convalescent plasma
  • +7 more outcomes

Companies that use Hemoclear

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Hemoclear technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Hemoclear partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Hemoclear competitors and assessment

Company assessment

Direct peers

  • LivaNova: LivaNova's Sorin Group legacy includes the XTRA and Electa autologous cell-salvage consoles, which compete directly with HemoClear in cardiac and major surgery settings.
  • Brightwake: Brightwake produces autologous blood filtration devices (e.g., Hemafuse) for surgical cell salvage in low-resource settings, making it one of the closest direct peers to HemoClear's gravity-driven filter concept.
  • Haemonetics: Haemonetics' Cell Saver system is the dominant centrifugal autologous blood cell-salvage device used in operating rooms globally, competing head-to-head with HemoClear's micro-filtration filter in surgical departments.

Emerging players

  • CytoSorbents: CytoSorbents' CytoSorb blood-purification technology operates in adjacent intraoperative and ICU blood-filtration applications, partially overlapping with HemoClear's positioning in surgical and critical-care blood management.
  • Velico Medical: Velico Medical focuses on front-line blood product processing and storage technologies for transfusion medicine, addressing a similar end-customer (blood banks and surgical teams) as HemoClear.
  • i-SEP: i-SEP is a French medtech developing an innovative autologous whole-blood filtration system for surgical and trauma settings, overlapping directly with HemoClear's filtration approach and target use cases.

Broad incumbents

  • Fresenius Kabi: Fresenius Kabi offers a broad portfolio of blood collection, processing, and transfusion devices (including CompoFlow and related consumables), positioning it as a broad incumbent across the transfusion-medicine supply chain that overlaps with HemoClear.
  • Medtronic (Perfusion/Cell Saver legacy): Medtronic's historical perfusion and cell-saver franchises (e.g., the autolog system) compete in the same surgical cell-salvage category as HemoClear, although Medtronic has a much broader device portfolio.
  • Terumo BCT: Terumo BCT provides Spectra Optia and other apheresis/cell-processing systems used in operating rooms and blood banks, serving as a broad incumbent in cell salvage and blood component processing.

Others

  • Pennine Healthcare: Pennine Healthcare is HemoClear's exclusive UK/Ireland distributor and co-developer of the HemoClear Accessories Kit, making it a partner rather than competitor but highly relevant as a channel comparison for autologous blood device go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Hemoclear social profiles

Digital presence

Hemoclear compliance and trust

Trust signal

Compliance2 records

Hemoclear financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemoclear leadership team

Management profile

Number of profiles

Profiles11 records

Hemoclear funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemoclear M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemoclear

What does Hemoclear do?

HemoClear develops and manufactures a gravity-driven micro-filtration autologous blood transfusion system. Its core product, the HemoClear Autologous Blood Filter, captures red blood cells and platelets from patient shed blood while filtering out plasma, toxins, and harmful agents, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The company sells filter kits, blood collection reservoirs, and accessories to hospitals, surgical departments, and global health programs.

Is Hemoclear a public or private company?

Hemoclear is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Hemoclear founded?

Hemoclear was founded in 2015. It employs 1 to 10 people.

Where is Hemoclear based?

Hemoclear is headquartered in Zwolle, Netherlands, in the Europe region.

How does Hemoclear make money?

Three revenue lines are on record. HemoClear Filter Kits are the primary driver. The others are accessories and Consumables and manufacturing Partnership with VDL.

Who are Hemoclear's main competitors?

Direct peers on record are LivaNova, Brightwake and Haemonetics. Emerging players are CytoSorbents, Velico Medical and i-SEP. Broad incumbents are Fresenius Kabi, Medtronic (Perfusion/Cell Saver legacy) and Terumo BCT. Pennine Healthcare is listed as an others.

Does Hemoclear have an API?

No public API is recorded for Hemoclear.

What industry is Hemoclear in?

Hemoclear's product category is Autologous Blood Transfusion Devices. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology, with a secondary code of HLAHAIAF, Infusion Pumps (Ambulatory/Stationary). Its NAICS code is 621991 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales